1. Home
  2. MTEM vs OGEN Comparison

MTEM vs OGEN Comparison

Compare MTEM & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MTEM
  • OGEN
  • Stock Information
  • Founded
  • MTEM N/A
  • OGEN 1996
  • Country
  • MTEM United States
  • OGEN United States
  • Employees
  • MTEM N/A
  • OGEN N/A
  • Industry
  • MTEM Biotechnology: Biological Products (No Diagnostic Substances)
  • OGEN Biotechnology: Pharmaceutical Preparations
  • Sector
  • MTEM Health Care
  • OGEN Health Care
  • Exchange
  • MTEM Nasdaq
  • OGEN Nasdaq
  • Market Cap
  • MTEM 8.5M
  • OGEN 9.8M
  • IPO Year
  • MTEM N/A
  • OGEN N/A
  • Fundamental
  • Price
  • MTEM $1.40
  • OGEN $1.13
  • Analyst Decision
  • MTEM
  • OGEN
  • Analyst Count
  • MTEM 0
  • OGEN 0
  • Target Price
  • MTEM N/A
  • OGEN N/A
  • AVG Volume (30 Days)
  • MTEM 29.2K
  • OGEN 122.4K
  • Earning Date
  • MTEM 08-08-2024
  • OGEN 08-12-2024
  • Dividend Yield
  • MTEM N/A
  • OGEN N/A
  • EPS Growth
  • MTEM N/A
  • OGEN N/A
  • EPS
  • MTEM N/A
  • OGEN N/A
  • Revenue
  • MTEM $31,763,000.00
  • OGEN $20,629.00
  • Revenue This Year
  • MTEM N/A
  • OGEN N/A
  • Revenue Next Year
  • MTEM N/A
  • OGEN N/A
  • P/E Ratio
  • MTEM N/A
  • OGEN N/A
  • Revenue Growth
  • MTEM N/A
  • OGEN N/A
  • 52 Week Low
  • MTEM $1.01
  • OGEN $0.97
  • 52 Week High
  • MTEM $9.45
  • OGEN $7.74
  • Technical
  • Relative Strength Index (RSI)
  • MTEM 51.89
  • OGEN 48.93
  • Support Level
  • MTEM N/A
  • OGEN N/A
  • Resistance Level
  • MTEM $1.40
  • OGEN $1.24
  • Average True Range (ATR)
  • MTEM 0.09
  • OGEN 0.06
  • MACD
  • MTEM -0.02
  • OGEN -0.01
  • Stochastic Oscillator
  • MTEM 92.20
  • OGEN 92.73

About MTEM Molecular Templates Inc.

Molecular Templates Inc is a clinical-stage biopharmaceutical company focused on developing therapeutic agents that selectively target tumor cells for the treatment of individuals living with cancer. Its pipeline products are MT-6402, MT-8421 and MT-0169.

About OGEN Oragenics Inc.

Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.

Share on Social Networks: